Latest Stroke Care News

Page 2 of 2

Argenica’s Phase 2 Stroke Trial Clears Safety Hurdle, Nears Completion

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

Ada Torres

30 Jan 2025

Top